Efficacy and safety of the combined use of celecoxib, diacerein and a combination of glucosamine and chondroitin for the control of musculoskeletal pain associated with osteoarthritis and nonspecific back pain
A. E. Karateev,E. Yu. Polishchuk,A. M. Lila,A. N. Ananyev,L. V. Ananyeva,A. V. Bondarev,A. A. Bondareva,A. R. Bukanbaeva,S. V. Vorster,S. A. Gadzhieva,D. G. Danilov,R. I. Eliseev,I. S. Zabelin,M. Yu. Ignatenko,I. V. Itkina,A. E. Kolesnikov,M. Yu. Konoplyanskaya,Yu. G. Krasnoyarova,S. I. Kukushkin,V. A. Lila,O. V. Makareva,V. S. Myagkikh,I. V. Nelgovskaya,N. V. Ocheredko,R. A. Panov,I. A. Polyakov,A. S. Prozorov,S. S. Rubina,M. E. Ryabochkina,M. A. Takhaev,E. R. Tokareva,T. V. Tolbina,M. I. Fominykh,V. V. Tsarev,E. I. Sharipova,M. V. Sheven,G. I. Shcherbakov,S. A. Yanchenkova
DOI: https://doi.org/10.14412/1996-7012-2023-5-97-106
2023-10-18
Modern Rheumatology Journal
Abstract:The combined use of drugs with different mechanisms of action is the main principle of musculoskeletal pain control in rheumatic diseases. However, there are few studies evaluating the efficacy of this approach in real practice.Objective: to determine the efficacy and safety of the combined use of celecoxib, diacerein, and the combination of glucosamine + chondroitin in osteoarthritis (OA) and chronic nonspecific low back pain (NSLBP). Material and methods. Statistical analysis of data obtained during a 3-month open observational study was performed. We included 1569 patients (63.6 % women and 36.4 % men, mean age 58.7 ± 11.0 years) with knee OA (kOA), hip OA (hOA), generalized OA (gOA), and chronic NSLBP with moderate/severe pain (≥ 4 on a numeric rating scale, NRS 0–10) who required nonsteroidal anti-inflammatory drugs. Celecoxib 200 mg twice daily was prescribed, with the dose reduced to 200 mg per day or taken “as needed" after significant pain relief; diacerein 50 mg twice daily; and a medication of glucosamine 250 mg and chondroitin 200 mg, 2 capsules 2–3 times daily. Outcomes were assessed after 3 months using the dynamics of pain, fatigue, dysfunction (according to NRS), and the “Patient Acceptable Symptom State” (PASS) indicator. Results and discussion. 80.2 % of patients completed the 3 month course of treatment, 4.4 % discontinued treatment due to adverse events (AEs), and for 15.4 % of patients there was no follow-up. After 3 months of treatment ≥ 50 % decrease (from baseline) in the severity of symptoms was noted in 83.4 % of patients for pain on movement, in 83.7 % for pain at rest, in 78.6 % for pain at night, in 80.8 % for dysfunction, and in 83.4 % for fatigue. 87.7 % of patients reported PASS. There were no significant differences in treatment outcomes for different localizations of OA and NSLBP: a ≥ 50 % pain reduction in kOA was achieved in 81.6 % of patients, in hOA – in 82.2 %, in gOA – in 85.0 %, in NSLBP – in 88.1 %. AEs were registered in 350 (22.4 %) patients, the most frequent was dyspepsia (n = 280, 17.8 %), diarrhea was recorded in 37 (2.4 %) cases. No serious AEs requiring hospitalization were registered. Conclusion. Combination therapy with celecoxib, diacerein, and a combination of glucosamine and chondroitin significantly reduces the severity of symptoms of OA and NSLBS.